DK1283839T3 - Adenosin A2a-receptorantagonister - Google Patents

Adenosin A2a-receptorantagonister

Info

Publication number
DK1283839T3
DK1283839T3 DK01945991T DK01945991T DK1283839T3 DK 1283839 T3 DK1283839 T3 DK 1283839T3 DK 01945991 T DK01945991 T DK 01945991T DK 01945991 T DK01945991 T DK 01945991T DK 1283839 T3 DK1283839 T3 DK 1283839T3
Authority
DK
Denmark
Prior art keywords
adenosine
receptor antagonists
antagonists
receptor
Prior art date
Application number
DK01945991T
Other languages
Danish (da)
English (en)
Inventor
Bernard R Neustadt
William J Greenlee
Deen Tulshian
Lisa S Silverman
Yan Xia
Craig D Boyle
Samuel Chackalamannil
Neil A Lindo
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DK1283839T3 publication Critical patent/DK1283839T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK01945991T 2000-05-26 2001-05-24 Adenosin A2a-receptorantagonister DK1283839T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20714300P 2000-05-26 2000-05-26
PCT/US2001/016954 WO2001092264A1 (en) 2000-05-26 2001-05-24 Adenosine a2a receptor antagonists
EP01945991A EP1283839B1 (en) 2000-05-26 2001-05-24 Adenosine a2a receptor antagonists

Publications (1)

Publication Number Publication Date
DK1283839T3 true DK1283839T3 (da) 2005-07-25

Family

ID=22769372

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01945991T DK1283839T3 (da) 2000-05-26 2001-05-24 Adenosin A2a-receptorantagonister

Country Status (31)

Country Link
US (4) US6630475B2 (cs)
EP (1) EP1283839B1 (cs)
JP (3) JP4574112B2 (cs)
KR (1) KR100520907B1 (cs)
CN (2) CN100384847C (cs)
AR (1) AR028621A1 (cs)
AT (1) ATE293627T1 (cs)
AU (2) AU6808901A (cs)
BR (1) BRPI0111015B8 (cs)
CA (1) CA2410237C (cs)
CZ (1) CZ303790B6 (cs)
DE (1) DE60110219T2 (cs)
DK (1) DK1283839T3 (cs)
EC (1) ECSP024364A (cs)
ES (1) ES2237576T3 (cs)
HK (1) HK1049007B (cs)
HU (1) HU230420B1 (cs)
IL (3) IL152726A0 (cs)
MX (1) MXPA02011625A (cs)
MY (1) MY132006A (cs)
NO (1) NO325008B1 (cs)
NZ (1) NZ522326A (cs)
PE (1) PE20020062A1 (cs)
PL (1) PL218764B1 (cs)
PT (1) PT1283839E (cs)
RU (1) RU2315053C2 (cs)
SI (1) SI1283839T1 (cs)
SK (1) SK287748B6 (cs)
TW (1) TWI288137B (cs)
WO (1) WO2001092264A1 (cs)
ZA (1) ZA200208898B (cs)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0111015B8 (pt) * 2000-05-26 2021-05-25 Merck Sharp & Dohme composto antagonista de receptor a2a de adenosina, composição farmacêutica compreendendo o mesmo, seu uso e processos para a preparação de compostos intermediários
MXPA04002389A (es) * 2001-09-13 2004-05-31 Schering Corp Combinacion de un antagonista del receptor de adenosian a2a y un antidepresivo o ansiolitico.
IL160878A0 (en) 2001-10-15 2004-08-31 Schering Corp Imidazo (4,3-e)-1,2,4-triazolo (1,5-c) pyrimidines as adenosine a2a receptor antagonists
FR2832405B1 (fr) * 2001-11-19 2004-12-10 Sanofi Synthelabo Tetrahydropyridyl-alkyl-heterocycles azotes, procede pour leur preparation et compositions pharmaceutiques les contenant
AU2002352933A1 (en) 2001-11-30 2003-06-17 Schering Corporation [1,2,4]-triazole bicylic adenosine A2a receptor antagonists
TW200300686A (en) 2001-11-30 2003-06-16 Schering Corp Adenosine A2a receptor antagonists
MXPA04005209A (es) * 2001-11-30 2004-08-19 Schering Corp Antagonistas del receptor de adenosina a2a.
AU2003207734C1 (en) 2002-01-28 2009-10-08 Kyowa Kirin Co., Ltd. Methods of treating patients suffering from movement disorders
US7064204B2 (en) 2002-05-30 2006-06-20 King Pharmacueticals Reserch And Development, Inc. Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
AU2003304527B2 (en) * 2002-12-19 2010-09-09 Merck Sharp & Dohme Corp. Uses of adenosine A2a receptor antagonists
US20060106040A1 (en) * 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
US20070010522A1 (en) 2003-04-09 2007-01-11 Chi Vu Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists
RU2373210C2 (ru) * 2003-04-23 2009-11-20 Шеринг Корпорейшн 2-АЛКИНИЛ- И 2-АЛКЕНИЛ-ПИРАЗОЛ-[4,3-e]-1, 2, 4-ТРИАЗОЛО-[1,5-c]-ПИРИМИДИНОВЫЕ АНТАГОНИСТЫ A2A РЕЦЕПТОРА АДЕНОЗИНА
US8202869B2 (en) * 2003-06-10 2012-06-19 Kyowa Hakko Kirin Co., Ltd. Method of treating an anxiety disorder
EP1636187A1 (en) * 2003-06-12 2006-03-22 Novo Nordisk A/S Substituted piperazine carbamates for use as inhibitors of hormone sensitive lipase
WO2005039506A2 (en) * 2003-10-24 2005-05-06 Exelixis, Inc. P70s6 kinase modulators and method of use
JP4782693B2 (ja) * 2003-10-28 2011-09-28 シェーリング コーポレイション 置換５−アミノ−ピラゾロ−［４，３−ｅ］−１，２，４−トリアゾロ［１，５−ｃ］ピリミジンを調製するためのプロセス
ATE377599T1 (de) 2003-12-01 2007-11-15 Schering Corp Verfahren zur herstellung von substituierten 5- aminopyrazolo(4,3-e)-1,2,4-triazolo(1,5- c)pyrimidinen
EP1701699B1 (en) * 2003-12-19 2011-07-13 Schering Corporation Pharmaceutical compositions of an A2a receptor antagonist
NZ550591A (en) 2004-04-21 2010-10-29 Schering Corp Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2A receptor antagonists
US7851478B2 (en) 2005-06-07 2010-12-14 Kyowa Hakko Kirin Co., Ltd. Agent for preventing and/or treating movement disorder
US7465740B2 (en) * 2005-09-19 2008-12-16 Schering Corporation 2-heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
PE20070521A1 (es) * 2005-09-23 2007-07-13 Schering Corp 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
JP5539717B2 (ja) * 2006-07-14 2014-07-02 塩野義製薬株式会社 オキシム化合物およびその使用
TW200840566A (en) * 2006-12-22 2008-10-16 Esteve Labor Dr Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments
US7723343B2 (en) * 2007-03-30 2010-05-25 King Pharmaceuticals Research And Development, Inc. Adenosine A2A receptor antagonists
US8669260B2 (en) * 2008-02-29 2014-03-11 Albert Einstein College Of Medicine Of Yeshiva University Ketoconazole-derivative antagonist of human pregnane X receptor and uses thereof
CA2717172A1 (en) 2008-03-04 2009-09-11 Schering Corporation 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists
CN102014959B (zh) 2008-03-10 2016-01-20 康奈尔大学 血脑屏障通透性的调节
TWI473614B (zh) * 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
CN102105168A (zh) 2008-07-23 2011-06-22 协和发酵麒麟株式会社 偏头痛治疗剂
US20100093702A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
WO2010078430A1 (en) 2008-12-30 2010-07-08 Arqule, Inc. Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds
AU2010207004A1 (en) 2009-01-20 2011-07-28 Merck Sharp & Dohme Corp. Methods of alleviating or treating signs and/or symptoms associated with moderate to severe Parkinson's disease
EP2389362B1 (en) 2009-01-21 2019-12-11 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
EP2405917B1 (en) 2009-03-13 2014-04-23 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
US8343961B2 (en) 2009-03-31 2013-01-01 Arqule, Inc. Substituted heterocyclic compounds
US8537177B2 (en) * 2009-06-15 2013-09-17 Marvell World Trade Ltd. System and methods for gamut bounded saturation adaptive color enhancement
WO2011017299A2 (en) 2009-08-07 2011-02-10 Schering Corporation PROCESS FOR PREPARING A 2-ALKYNYL SUBSTITUTED 5-AMINO-PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE
CA2812683C (en) 2009-09-25 2017-10-10 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
US9616058B2 (en) 2010-02-24 2017-04-11 Oryzon Genomics, S.A. Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
WO2011106106A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
RS55348B1 (sr) 2010-04-19 2017-03-31 Oryzon Gnomics S A Inhibitori lizin specifične demetilaze-1 i njihova upotreba
EP2598480B1 (en) 2010-07-29 2019-04-24 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
CN104892525A (zh) 2010-07-29 2015-09-09 奥瑞泽恩基因组学股份有限公司 Lsd1的基于芳基环丙胺的脱甲基酶抑制剂及其医疗用途
CN103261202B (zh) * 2010-09-24 2016-01-20 阿迪维纳斯疗法有限公司 作为腺苷受体拮抗剂的稠合三环化合物
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP3981395A1 (en) 2011-02-08 2022-04-13 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
WO2012127472A1 (en) * 2011-03-22 2012-09-27 Mapi Pharma Ltd. Process and intermediates for the preparation of preladenant and related compounds
WO2012129381A1 (en) * 2011-03-22 2012-09-27 Concert Pharmaceuticals Inc. Deuterated preladenant
WO2013024474A1 (en) * 2011-08-18 2013-02-21 Mapi Phrarma Ltd. Polymorphs of preladenant
CN104203914B (zh) 2011-10-20 2017-07-11 奥瑞泽恩基因组学股份有限公司 作为lsd1抑制剂的(杂)芳基环丙胺化合物
WO2013057322A1 (en) 2011-10-20 2013-04-25 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
WO2014071512A1 (en) * 2012-11-06 2014-05-15 Universite Laval Combination therapy and methods for the treatment of respiratory diseases
WO2014101120A1 (en) * 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
CN107106558A (zh) 2014-11-18 2017-08-29 默沙东公司 具有a2a拮抗剂性质的氨基吡嗪化合物
US10138212B2 (en) 2015-02-06 2018-11-27 Merck Sharp & Dohme Corp. Aminoquinazoline compounds as A2A antagonist
EP3307067B1 (en) 2015-06-11 2022-11-02 Merck Sharp & Dohme LLC Aminopyrazine compounds with a2a antagonist properties
WO2017008205A1 (en) 2015-07-10 2017-01-19 Merck Sharp & Dohme Corp. Substituted aminoquinazoline compounds as a2a antagonist
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
JP7197558B2 (ja) * 2017-03-30 2022-12-27 アイテオ ベルギウム エスエー Ａ２ａ阻害剤及び癌の治療に使用するための化合物としての２－オキソ－チアゾール誘導体
TWI801372B (zh) * 2017-03-30 2023-05-11 比利時商艾特歐斯比利時有限公司 作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法
EP3723754A4 (en) 2017-12-13 2021-05-19 Merck Sharp & Dohme Corp. IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES
ES2928238T3 (es) * 2018-01-04 2022-11-16 Impetis Biosciences Ltd Compuestos tricíclicos, composiciones y aplicaciones medicinales de los mismos
TWI877770B (zh) 2018-02-27 2025-03-21 美商英塞特公司 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶
CN108276345A (zh) * 2018-03-22 2018-07-13 重庆奥舍生物化工有限公司 一种药物中间体嘧啶-5-甲醛的制备方法
KR20200140849A (ko) 2018-04-08 2020-12-16 베이진 엘티디 A2a 수용체 길항제로서의 피라졸로트리아졸로피리미딘 유도체
JP7391046B2 (ja) 2018-05-18 2023-12-04 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体
CN108864114B (zh) * 2018-06-04 2020-11-06 应世生物科技(南京)有限公司 选择性a2a受体拮抗剂
PE20211807A1 (es) 2018-07-05 2021-09-14 Incyte Corp Derivados de pirazina fusionados como inhibidores de a2a/a2b
CN110742893B (zh) * 2018-07-23 2024-04-05 百济神州(北京)生物科技有限公司 A2a受体拮抗剂治疗癌症的方法
AR117164A1 (es) 2018-11-30 2021-07-14 Merck Sharp & Dohme Derivados de amino-triazoloquinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso para el tratamiento de diversos tipos de cáncer
MA54551A (fr) 2018-12-20 2021-10-27 Incyte Corp Composés d'imidazopyridazine et d'imidazopyridine utilisés en tant qu'inhibiteurs de la kinase 2 de type récepteur de l'activine
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US12325708B2 (en) 2019-05-03 2025-06-10 Nektar Therapeutics Adenosine 2 receptor antagonists
DE102019116986A1 (de) 2019-06-24 2020-12-24 Helmholtz-Zentrum Dresden-Rossendorf E. V. Deuterierte 7-(3-(4-(2-([18F]Fluor)ethoxy)phenyl)propyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amin-Derivate
EP3999513A4 (en) * 2019-07-17 2022-12-21 Teon Therapeutics, Inc. ADENOSIN A2A RECEPTOR ANTAGONISTS AND USES THEREOF
CN112625050B (zh) 2019-07-30 2021-10-01 杭州阿诺生物医药科技有限公司 一种a2a和/或a2b受体抑制剂的制备方法
CN112479956A (zh) 2019-07-30 2021-03-12 杭州阿诺生物医药科技有限公司 一种用于制备腺苷受体抑制剂中间体的方法
CN111072675A (zh) * 2019-12-12 2020-04-28 广东东阳光药业有限公司 含氮稠合三环衍生物及其用途
CN113773327B (zh) * 2021-09-13 2022-07-15 八叶草健康产业研究院(厦门)有限公司 一种吡唑并嘧啶并三唑环类化合物的制备方法
CN118812544A (zh) * 2024-06-19 2024-10-22 厦门大学 一种腺苷a2ar靶向小分子化合物、核素标记探针及其制备方法、应用和药物组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3677445D1 (de) 1985-09-30 1991-03-14 Ciba Geigy Ag 2-substituierte-e-kondensierte(1,5-c)-pyrimidine, pharmazeutische zubereitungen und ihre verwendung.
SU1739850A3 (ru) * 1987-08-31 1992-06-07 Такеда Кемикал Индастриз, Лтд (Фирма) Способ получени конденсированных производных пиразоло[3,4- @ ]пиримидина
IT1264901B1 (it) * 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
AU7237294A (en) 1993-07-27 1995-02-28 Kyowa Hakko Kogyo Co. Ltd. Remedy for parkinson's disease
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) * 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
BRPI0111015B8 (pt) * 2000-05-26 2021-05-25 Merck Sharp & Dohme composto antagonista de receptor a2a de adenosina, composição farmacêutica compreendendo o mesmo, seu uso e processos para a preparação de compostos intermediários
MXPA04005209A (es) * 2001-11-30 2004-08-19 Schering Corp Antagonistas del receptor de adenosina a2a.
AU2003304527B2 (en) * 2002-12-19 2010-09-09 Merck Sharp & Dohme Corp. Uses of adenosine A2a receptor antagonists
JP4782693B2 (ja) * 2003-10-28 2011-09-28 シェーリング コーポレイション 置換５−アミノ−ピラゾロ−［４，３−ｅ］−１，２，４−トリアゾロ［１，５−ｃ］ピリミジンを調製するためのプロセス
ATE377599T1 (de) * 2003-12-01 2007-11-15 Schering Corp Verfahren zur herstellung von substituierten 5- aminopyrazolo(4,3-e)-1,2,4-triazolo(1,5- c)pyrimidinen
NZ550591A (en) * 2004-04-21 2010-10-29 Schering Corp Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2A receptor antagonists
US7465740B2 (en) * 2005-09-19 2008-12-16 Schering Corporation 2-heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Also Published As

Publication number Publication date
US6897216B2 (en) 2005-05-24
AU2001268089C1 (en) 2006-04-13
NO20025651D0 (no) 2002-11-25
US6630475B2 (en) 2003-10-07
PT1283839E (pt) 2005-08-31
NZ522326A (en) 2006-03-31
BR0111015A (pt) 2005-01-11
BRPI0111015B1 (pt) 2017-11-07
AU2001268089B2 (en) 2005-04-28
ECSP024364A (es) 2003-03-31
US20040023997A1 (en) 2004-02-05
JP2006219497A (ja) 2006-08-24
MXPA02011625A (es) 2003-03-27
CZ303790B6 (cs) 2013-05-09
CN1451007A (zh) 2003-10-22
KR20030003746A (ko) 2003-01-10
BRPI0111015B8 (pt) 2021-05-25
ES2237576T3 (es) 2005-08-01
IL152726A0 (en) 2003-06-24
SI1283839T1 (cs) 2005-08-31
CN100384847C (zh) 2008-04-30
WO2001092264A1 (en) 2001-12-06
JP2007145875A (ja) 2007-06-14
USRE44205E1 (en) 2013-05-07
JP2003535094A (ja) 2003-11-25
IL220174A0 (en) 2012-07-31
HUP0600239A2 (en) 2006-07-28
US20020099061A1 (en) 2002-07-25
NO325008B1 (no) 2008-01-14
AU6808901A (en) 2001-12-11
SK287748B6 (sk) 2011-08-04
HK1049007B (en) 2005-09-16
DE60110219T2 (de) 2006-03-09
ZA200208898B (en) 2004-03-01
NO20025651L (no) 2003-01-23
HU230420B1 (hu) 2016-05-30
ATE293627T1 (de) 2005-05-15
EP1283839B1 (en) 2005-04-20
US20050026932A1 (en) 2005-02-03
AR028621A1 (es) 2003-05-14
TWI288137B (en) 2007-10-11
US7067655B2 (en) 2006-06-27
SK16712002A3 (sk) 2003-08-05
RU2315053C2 (ru) 2008-01-20
EP1283839A1 (en) 2003-02-19
CN1247588C (zh) 2006-03-29
CA2410237C (en) 2008-01-08
IL152726A (en) 2012-07-31
CZ20023886A3 (cs) 2003-02-12
HK1049007A1 (en) 2003-04-25
KR100520907B1 (ko) 2005-10-11
MY132006A (en) 2007-09-28
JP4938348B2 (ja) 2012-05-23
PL218764B1 (pl) 2015-01-30
HUP0600239A3 (en) 2008-06-30
DE60110219D1 (de) 2005-05-25
CA2410237A1 (en) 2001-12-06
CN1800186A (zh) 2006-07-12
JP4574112B2 (ja) 2010-11-04
PL360472A1 (en) 2004-09-06
PE20020062A1 (es) 2002-02-02
IL220174A (en) 2015-07-30

Similar Documents

Publication Publication Date Title
ATE293627T1 (de) Adenosin a2a rezeptor antagonisten
DE60234951D1 (de) Adenosin a2a rezeptor antagonisten
DE60209251D1 (de) Adenosine a2a receptor antagonisten
DE60219196D1 (de) BICYCLISCHE Ä1,2,4ö-TRIAZOL ADENOSIN A2a REZEPTOR ANTAGONISTEN
ATE256141T1 (de) N-pyrazol a2a rezeptor agonisten
DE60002722D1 (de) C-pyrazol a2a rezeptor agonisten
IS5706A (is) Adenosín A3 viðtakastillar
HUP0401925A3 (en) A2b adenosine receptor antagonists
NO20024006D0 (no) Adenosinreseptor modulatorer
NO20032277L (no) Aminotiazoler og deres anvendelse som adenosinreseptorantagonister
ATE273989T1 (de) Adenosin a1-rezeptor agonisten
DE69815378D1 (de) Adenosin a1-rezeptor agonisten
DE69825780D1 (de) Adenosin a1-rezeptor agonisten
ID29996A (id) Penentuan lokasi menggunakan regresi daerah bobot
DK1192170T3 (da) Propargylphenylether A2A-receptoragonister
NO20020979D0 (no) Selektive A2B-adenosin reseptorantagonister
ATE432282T1 (de) 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten
ATE394402T1 (de) Kondensierte purinderivate als a1- adenosinrezeptorantagonisten
DE60106974D1 (de) Aminotriazolopyridinderivate als adenosinrezeptorliganden
NO20015662D0 (no) Oralt aktive A1-adenosinreseptorantagonister
DE60220713D1 (de) Ribofuranosyluronamid Derivate als Kristall; ein menschlicher Adenosin A2A Rezeptor Agonsit
EP1295891A4 (en) Nucleoside derivatives
DK1090019T3 (da) Adenosinderivater
SE9901473D0 (sv) Nucleosides
SE0003996D0 (sv) Receptorantagonister